IMPLANET: 23% growth in half-year revenue for 2026

IMPLANET, a specialist in medical technologies, announces a 23% increase in revenue for the first half of 2026, reaching €7.1 million. Operating profit improved by 13% thanks to continued growth and a 7-point increase in gross margin to 59.5%. Sales of the Jazz Spinal System, a hybrid posterior fixation system, doubled, particularly boosting performance in the United States, with a 54% increase.

Operating costs nevertheless increased by 18% due to commercial investments. The operating loss decreased to €1.87 million. The company plans to strengthen its presence in the United States, roll out its strategic product lines, and position itself as a key partner in artificial intelligence and robotics.